Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT.

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

2.

Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.

Caldarola G, Sollena P, Peris K, De Simone C.

J Dermatol. 2015 Jul;42(7):753-4. doi: 10.1111/1346-8138.12894. Epub 2015 Apr 20. No abstract available.

PMID:
25899558
3.

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.

Yeo SI.

Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 Apr 26. Review.

PMID:
23981744
4.

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.

Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W.

Pharmacogenet Genomics. 2009 Sep;19(9):704-9. doi: 10.1097/FPC.0b013e328330a3b8.

PMID:
19696695
5.

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Zineh I, Mummaneni P, Lyndly J, Amur S, La Grenade LA, Chang SH, Rogers H, Pacanowski MA.

Pharmacogenomics. 2011 Dec;12(12):1741-9. doi: 10.2217/pgs.11.131.

PMID:
22118056
7.

HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.

Gonçalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R, Martinho A.

Br J Dermatol. 2013 Sep;169(3):660-5. doi: 10.1111/bjd.12389.

PMID:
23600531
8.

HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population.

Niihara H, Kaneko S, Ito T, Sugamori T, Takahashi N, Kohno K, Morita E.

J Dermatol Sci. 2013 Aug;71(2):150-2. doi: 10.1016/j.jdermsci.2013.04.013. Epub 2013 Apr 19. No abstract available.

PMID:
23669020
9.

HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.

Cheng L, Xiong Y, Qin CZ, Zhang W, Chen XP, Li J, Zhou HH.

Br J Dermatol. 2015 Aug;173(2):555-8. doi: 10.1111/bjd.13688. Epub 2015 Jun 22. No abstract available.

PMID:
26104483
10.

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW; Adverse Drug Reaction Research Group in Korea.

Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8. Erratum in: Pharmacogenet Genomics. 2012 Aug;22(8):652.

PMID:
21301380
11.

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.

Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP.

Am J Med. 2016 Nov;129(11):1221-1225. doi: 10.1016/j.amjmed.2016.03.022. Epub 2016 Apr 15.

PMID:
27086495
12.

HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.

Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, Lee JH.

Yonsei Med J. 2016 Jan;57(1):118-26. doi: 10.3349/ymj.2016.57.1.118.

13.

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR.

Nephrol Dial Transplant. 2011 Nov;26(11):3567-72. doi: 10.1093/ndt/gfr060. Epub 2011 Mar 10.

PMID:
21393610
14.

HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.

Kano Y, Hirahara K, Asano Y, Shiohara T.

Acta Derm Venereol. 2008;88(6):616-8. doi: 10.2340/00015555-0528. No abstract available.

15.

Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea.

Lee HS, Ueta M, Kim MK, Seo KY, Sotozono C, Kinoshita S, Yoon KC.

Cornea. 2016 Feb;35(2):199-204. doi: 10.1097/ICO.0000000000000708.

PMID:
26655481
16.

Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.

Fernando SL, Broadfoot AJ.

CMAJ. 2010 Mar 23;182(5):476-80. doi: 10.1503/cmaj.090401. Epub 2009 Nov 23. No abstract available.

17.

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.

Yun J, Mattsson J, Schnyder K, Fontana S, Largiadèr CR, Pichler WJ, Yerly D.

Clin Exp Allergy. 2013 Nov;43(11):1246-55. doi: 10.1111/cea.12184.

PMID:
24152157
18.

Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.

Ng CY, Yeh YT, Wang CW, Hung SI, Yang CH, Chang YC, Chang WC, Lin YJ, Chang CJ, Su SC, Fan WL, Chen DY, Wu YJ, Tian YC, Hui RC, Chung WH; Taiwan Severe Cutaneous Adverse Reaction Consortium.

J Invest Dermatol. 2016 Jul;136(7):1373-1381. doi: 10.1016/j.jid.2016.02.808. Epub 2016 Mar 18.

19.

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.

Pharmacogenomics. 2008 Nov;9(11):1617-22. doi: 10.2217/14622416.9.11.1617.

PMID:
19018717
20.

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.

Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group.

J Am Acad Dermatol. 2008 Jan;58(1):25-32. Epub 2007 Oct 24.

PMID:
17919772

Supplemental Content

Support Center